Sengenics Corporation Announces Key Distributor in China

February 27, 2024 11:30 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Sengenics Partners with Shanghai Universal Biotech Co., Ltd. (UniV) to Expand Reach of Immunoprofiling Products and Services in China

BOSTON, Feb. 27, 2024 /PRNewswire/ -- Sengenics Corporation LLC, a pioneer in the field of immunoproteomic biomarker discovery, proudly announces that it has entered into a sales distribution and services agreement with Chinese distributor Shanghai Universal Biotech Co., Ltd. ("UniV"). This agreement marks a significant step in expanding the reach of Sengenics' KREX® technology in Asia, bringing advanced capabilities for profiling autoantibodies and protein interactions to a broad spectrum of pharmaceutical, biotech, and academic institutions throughout China.

"Sengenics is thrilled to partner with UniV, which has a reputation for excellence and an expert team of skilled technical and commercial specialists," said Jerry Williamson, Chief Executive Officer of Sengenics. "This collaboration isn't just about expanding our reach in Asia; it's about bringing the transformative power of immunoprofiling to enhance our understanding of disease and improve patient care."

Echoing this sentiment, Yin Zhou, VP of Marketing at UniV remarked, "As a comprehensive multiomics and multiplex distributor and service company, we are committed to the frontier of biomarker discovery. This strategic partnership with Sengenics, a leading provider of cutting-edge technology for autoantibody biomarker discovery, underscores our dedication to advancing biomarker discovery, driving translational medicine, and contributing to human health."

Sengenics and UniV are committed to enriching the immunoprofiling field, exploring new markets, and broadening the reach of the innovative KREX® technology to serve a wider community of researchers and clinicians.

About Sengenics
Sengenics is an immunoproteomics company working to improve patient outcomes through physiologically relevant, data-guided decision making. Our solutions enable the discovery and validation of antibody biomarker signatures for patient stratification, therapeutic response prediction and development of companion diagnostics. Sengenics Corporation LLC is headquartered in Greater Boston, Massachusetts, USA and has offices worldwide. Sengenics has more than 50 employees across its current locations.
www.sengenics.com

About Shanghai Universal Biotech Co., Ltd.
Established in 2004, Shanghai Universal Biotech Co., Ltd. (UniV, Stock code: 301166) is a leading antibody supplier dedicated to advancing life science innovation. With a vast network of 26 offices and 10 sales subsidiaries in China, UniV is on a mission to become the go-to distributor for life sciences, providing an extensive catalog of over 7 million antibody-based reagents, consumables, instruments, software, customization, laboratory services and supply chain services. Expanding its research and development capabilities, UniV inaugurated the Nanjing R&D Center in 2018 and the Hangzhou R&D Center in 2021. It also invested in a GMP-level production center in Nanjing in 2021 to meet the needs of industrial customers in the life sciences sector.
www.univ-bio.com 

Investor Contact
Jerry Williamson, President & CEO, Sengenics Corporation
[email protected]

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.